Breast Cancer

Douglas Yee, MD, explains current treatment options and ongoing research aimed at optimizing neoadjuvant therapy for HER2-positive breast cancer.

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, gives advice for community-based oncologists regarding HER2 testing and interpretation of the results.

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the efficacy of pembrolizumab and atezolizumab for the treatment of patients with metastatic triple-negative breast cancer.

Rowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California, Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses a planned follow-up analysis of the Women's Health Initiative Dietary Modification study, which examined the impact of reduced dietary fat intake in patients with breast cancer.

PIK3CA mutations and low/no expression of PTEN correlated with an extension in progression-free survival for patients with metastatic HER2-positive breast cancer treated with the combination of everolimus, trastuzumab, and paclitaxel.

Chemotherapy-free neoadjuvant treatment with trastuzumab emtansine demonstrated a pathological complete response rate of 40.5% in patients with HER2+ and HR+ early breast cancer.

Ruth M. O'Regan, MD, discusses two of her studies in HER2-positive breast cancer presented at ASCO 2015.

Francisco J. Esteva, MD, PhD, professor, Department of Medicine, associate director, Clinical Investigation Perlmutter Cancer Center, director, Breast Medical Oncology Program, NYU Langone Medical Center, discusses the efficacy of T-DM1 in patients with HER2-positive breast cancer.

Over the past several decades, breast-conserving therapy has emerged as the standard of care in the management of early-stage breast cancer.

For insight on the potential of ONT-380 in HER2-positive breast cancer, OncLive spoke with the lead author of the primary phase Ib analysis, Erika P. Hamilton, MD.